Memantine
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Memantine: From Alzheimer's Disease to Pulmonary Hypertension
One-Sentence Summary
Memantine is an NMDA receptor antagonist best known for treating moderate-to-severe Alzheimer's disease dementia. The TxGNN model's top-ranked prediction suggests it may be effective for Pulmonary Hypertension, but this direction is currently supported only by mechanistic literature — 0 registered clinical trials and 2 supporting publications, with no dedicated efficacy studies of memantine itself in this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer's disease (moderate-to-severe dementia) — based on the drug's known clinical profile; not confirmed via the Finland registry, as the drug is currently unmarketed there |
| Predicted New Indication | Pulmonary Hypertension |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L4 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for memantine is not available in this evidence pack (data gap, high severity). Based on general drug knowledge, memantine is a moderate-affinity, uncompetitive NMDA (N-methyl-D-aspartate) receptor antagonist, with proven efficacy in Alzheimer's disease dementia by modulating glutamatergic neurotransmission.
The mechanistic bridge to pulmonary hypertension comes from the glutamate/NMDAR signaling axis, which has been implicated beyond the central nervous system — including in acute lung injury and pulmonary arterial hypertension pathophysiology (PMID 33500723). This suggests NMDAR blockade could plausibly affect pulmonary vascular remodeling, though this is preclinical/mechanistic evidence rather than direct clinical proof in memantine itself.
Notably, a nitrate derivative of memantine (MN-08) is already in clinical development specifically for pulmonary arterial hypertension, having completed a Phase 1 single/multiple ascending dose safety and pharmacokinetics study in healthy volunteers (PMID 41739394). This is a meaningful signal — it indicates industry interest in the memantine/NMDAR scaffold for this exact indication — but it is evidence for a related compound, not for memantine itself, and no efficacy data yet exists for either molecule in pulmonary hypertension patients.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33500723 | 2021 | Mechanism study | Theranostics | Glutamate/NMDAR axis implicated in acute lung injury, pulmonary arterial hypertension, and diabetes; explores metabolic role in insulin sensitivity/lipid metabolism |
| 41739394 | 2026 | Phase 1 PK/safety study | Clinical Drug Investigation | MN-08, a nitrate derivative of memantine under development for pulmonary arterial hypertension, shown safe and tolerable in single/multiple ascending dose study in healthy Chinese volunteers |
Finland Market Information
Memantine is not currently marketed in Finland (未上市); no marketing authorizations are on record in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA package insert warnings/contraindications are flagged as a Blocking data gap (DG001) — they must be obtained before any S1 safety pre-assessment can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The pulmonary hypertension signal rests entirely on mechanistic literature and a Phase 1 PK study of a memantine analog (not memantine itself) — there are no registered clinical trials or efficacy data for memantine in this indication, so the evidence base is too thin to advance.
To proceed, the following is needed:
- TFDA/official package insert warnings and contraindications (Blocking data gap — required before any safety pre-assessment)
- Confirmed mechanism of action (MOA) documentation from DrugBank (High-severity data gap — needed to substantiate the mechanistic rationale)
- Direct preclinical or clinical efficacy data for memantine (not just its analog MN-08) in pulmonary hypertension
- Monitoring of MN-08 clinical development, as positive results there would meaningfully strengthen this repurposing case
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.